RT Journal Article
SR Electronic
T1 Correlation between prescribing quality and pharmaceutical costs in English primary care: national cross-sectional analysis
JF British Journal of General Practice
JO Br J Gen Pract
FD British Journal of General Practice
SP e556
OP e564
DO 10.3399/bjgp11X593839
VO 61
IS 590
A1 Robert Fleetcroft
A1 Richard Cookson
A1 Nicholas Steel
A1 Amanda Howe
YR 2011
UL http://bjgp.org/content/61/590/e556.abstract
AB Background Both pharmaceutical costs and quality-indicator performance vary substantially between general practices, but little is known about the relationship between prescribing costs and qualityAim To measure the association between prescribing quality and pharmaceutical costs among English general practicesDesign and setting Cross-sectional observational study using data from the Quality and Outcomes Framework and the Prescribing Analysis and Cost database from all 8409 general practices in England in 2005-2006Method Correlation between practice achievement of 26 prescribing quality indicators in eight prescribing areas and related pharmaceutical costs was examined.Results There was no significant association between the overall achievement of quality indicators and related pharmaceutical costs (P= 0.399). Mean achievement of quality indicators across all eight prescribing areas was 79.0% (standard deviation 4.4%). There were small positive correlations in five prescribing areas: influenza vaccination, beta blockers, angiotensin converting enzyme inhibitors, lipid lowering, and antiplatelet treatment (all P<0.001). There were small negative correlations in two prescribing areas: hypertension (P<0.001) and smoking cessation (P = 0.018).Conclusion Correlations between prescribing quality and pharmaceutical costs were much smallerthan expected; possible explanations forthis include a substantial variation in rates of prescribing outside evidence-based protocols, and use of expensive pharmaceuticals instead of cheaper effective alternatives. There remains considerable scope for some practices to make pharmaceutical cost savings while improving quality performance. The ratio of quality scores to related pharmaceutical costs could be developed into a performance indicator